Venture Eyes Ophthalmology--And Likes What It Sees

Ophthalmology has long been a bright spot for venture investors given the potential market size, health care burden, and high unmet medical need associated with many eye diseases. Based on a recent analysis by Start-Up magazine, there is no sign that trend is diminishing. Using Elsevier's Strategic Transactions database, Start-Up found that private backers have poured nearly $1.8 billion into 58 ophthalmology start-ups since 1999, with the money split nearly 50/50 in terms of device and drug investments. This trend is likely to accelerate as a number of new acquirers emerge to play in what was once a niche area.

On October 1, Sanofi and the ophthalmology start-up Fovea Pharmaceuticals SA announced a $538 million marriage that unequivocally demonstrates the French pharmaceutical company's interest in developing treatments for eye diseases. [See Deal] Fovea, which has a mid-stage clinical program for allergic conjunctivitis and earlier ones for macular edema, will become Sanofi's eyes in ophthalmology, operating as an independent business unit to build the drug maker's pipeline via a combination of in-licensing and in-house development.

Sanofi is by no means the only large health care company to awaken to the potential of ophthalmology. Lured by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business